There was at least an initial attempt on the part of Apotex to seek voluntary licences. It's a triple-fixed dose so they tried to seek licences from the relative patentees. At that time, there wasn't a country of mention, so there was some discussion on whether that was a bona fide attempt to seek a licence. There was some correspondence sent into us, but we deferred it to the Commissioner of Patents, where it belongs. It's really, as I said, an issue that has to go between the generic company and the patentees. We've only had an opportunity to watch it from a distance.
On April 16th, 2007. See this statement in context.